20,426
Participants
Start Date
November 14, 2019
Primary Completion Date
January 31, 2022
Study Completion Date
February 28, 2022
Ad26.ZEBOV, MVA-BN-Filo vaccine
"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
L'Institut National de Recherche Biomédicale RDC, Kinshasa
Collaborators (1)
Epicentre
OTHER
Ministère de la Santé de la RDC
UNKNOWN
Médecins Sans Frontières, France
OTHER
Coalition for Epidemic Preparedness Innovations
OTHER
Janssen Vaccines & Prevention B.V.
INDUSTRY
Public Health England
OTHER_GOV
London School of Hygiene and Tropical Medicine
OTHER